Impact of IL-4/IL-13 Blockade with Dupilumab on the Microbiome in Type 2 Inflammatory Diseases: A Systematic Review - PubMed
2 days ago
- #Type 2 Inflammation
- #Microbiome
- #Dupilumab
- Dupilumab treatment is associated with reduced Staphylococcus aureus and increased microbial diversity on the skin in atopic dermatitis.
- Sinonasal studies indicate dupilumab shifts microbial communities toward a more eubiotic state in conditions like chronic rhinosinusitis with nasal polyps.
- Gut microbiome changes with dupilumab are less defined, though one study suggests modulation of tryptophan metabolism-related pathways.
- Effects of dupilumab on the microbiome are compartment-specific and vary by disease, with the strongest evidence for skin and sinonasal sites.
- Further prospective studies are needed to explore microbiota signatures as potential biomarkers for treatment response.